Gleamer vs Infervision

Chest imaging is the overlap, split by modality. Gleamer's ChestView reads chest X-ray for pneumothorax, consolidation, nodule, mediastinal mass and pleural effusion, and openFDA lists ChestView US as K241620 (February 2025) and K252486 (September 2026). Infervision's openFDA records under its three applicant names include InferRead Lung CT.AI for nodule detection (K192880, July 2020, and K240554, May 2025), CT Stroke.AI (K211179), InferOperate Suite and InferCare RECIST. Infervision lists InferRead DR Chest for chest X-ray, and that product has no record among them. Gleamer lists LungCT for CT nodules, and no record for it appears under Gleamer's applicant names, so its US status is not established.

A 2025 PLOS Global Public Health evaluation by independent academic authors tested InferRead DR Chest for TB screening in Lusaka, Zambia, and reported 90.3% sensitivity and 39.2% specificity at a 0.12 cut-off.

For a US radiology group buying chest X-ray AI, Infervision trails Gleamer, since ChestView has two chest X-ray records and DR Chest has none. A group reading lung nodules on CT gets the opposite answer, since InferRead Lung CT.AI has two records and Gleamer's LungCT US status is not established.